Loading...

Antihyperlipidemic Drugs Market by Drug Class (Statins, PCSK9 Inhibitors, Bile Acid Sequestrants, Cholesterol Absorption Inhibitors, Fibric Acid Derivatives, and Combination): Global Opportunity Analysis and Industry Forecast, 2019–2026

A05919
Pages: 184
Dec 2019 | 1602 Views
 
Author(s) : Sagar Mukhekar , Onkar Sumant
Tables: 62
Charts: 57
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Antihyperlipidemic Drugs Market

Request Now !

The global antihyperlipidemic drugs market accounted for $9,456 million in 2018, and is expected to reach $16,865 million by 2026, registering a CAGR of 7.5% from 2019 to 2026. 

Lipids are chemical substances that are insoluble in water such as cholesterol and triglycerides. Hyperlipidemia is a medical condition marked by elevation of lipid level in the blood. This rise in lipid levels leads to increase in fatty deposits in arteries, which cause blockages in the arteries of the patient. The blockages can in turn lead to rise in risk related to heart attacks. Therefore, hyperlipidemia is a major medical condition that requires treatment. The drugs that are used to treat hyperlipidemia are called as antihyperlipidemic drugs. Some of the drugs available in the market include bile acid, sequestrants, cholesterol absorption inhibitors, and others.  

Antihyperlipidemic Drugs Market

Get more information on this report : Request Sample Pages

 

The factors that contribute for the growth of the market include surge in sedentary lifestyle. Furthermore, rise in incidence of disorders related to distributed cholesterol levels in the blood also contributes to the growth of the antihyperlipidemic drugs market. Moreover, surge in awareness regarding complications related with hyperlipidemia is another major factor that fuels the growth of the market. However, high cost of the treatment hinders the growth of the market. Conversely, growth opportunities exhibited by emerging economies is expected to offer lucrative opportunities during the forecast period.    

Antihyperlipidemic Drugs Market Segmentation  

The antihyperlipidemic drugs market size is studied based on segments, drug class and region to provide a detailed assessment of the market. Based on drug class, the market is divided into statins, pcsk9 inhibitors, bile acid sequestrants, cholesterol absorption inhibitors, fibric acid derivatives, and combination. Based on region, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, and rest of LAMEA). 

Segment Review

According to drug class, statins occupied the largest antihyperlipidemic drugs market share in 2018, owing to surge in the incidence of cardiovascular disorders. Furthermore, statins reduce the risk associated with heart attacks which is another major factor that contributes to the growth of the market. Moreover, PCSK9 inhibitors is expected to register the fastest growth during the forecast period, owing to the benefits offered such as drastic reduction of LDL levels in the blood. The other factors that boost the antihyperlipidemic drugs market growth include the surge in the geriatric population and rise in healthcare expenditure across the globe. In addition, the other factors which boost the growth of the market include the additional benefits offered by the statins such as improved endothelial function, enhance the stability of atherosclerotic plaques, and reduce the amount of inflammation & damage done to cells due to oxidative stress.

Antihyperlipidemic Drugs Market
By Drug Class

Your browser does not support the canvas element.

Dialysis instrument segment holds a dominant position in 2018 and would continue to maintain the lead over the forecast period.

Get more information on this report : Request Sample Pages

By region, North America accounted for the major antihyperlipidemic drugs market share in 2018, and is expected to continue this trend due to easy availability of the antihyperlipidemic drugs. Moreover, surge in sedentary lifestyle in the region is another major factor that contributes to the growth of the market. Furthermore, surge in the obese population is another major factor that fuels the growth of the antihyperlipidemic drugs market. In addition, the presence of major key players such as Abbvie Inc., Amgen Inc., Bristol-Myers Squibb Company, Merck & Co., Inc. and others is another major factor that fuels the growth of antihyperlipidemic drugs market in the region. On the other side, Asia-Pacific is estimated to register the fastest growth during the forecast period, owing to surge in awareness related to the use of antihyperlipidemic drugs. The constantly evolving life science industry drives the growth of the market in the developing economies such as India, China, Malaysia, and others.

Antihyperlipidemic Drugs Market
By Region

2026
North America 
Europe
Asia-pacific
Lamea

Asia-Pacific region would exhibit the highest CAGR of 8.6% during 2019-2026.

Get more information on this report : Request Sample Pages

The global antihyperlipidemic drugs market is highly competitive and the prominent players in the market have adopted various strategies for garnering maximum market share. These include collaboration, product launch, partnership, and acquisition. Major players operating in the market include Boehringer Ingelheim GmbH, Merck KGaA, Johnson and Johnson, Bayer AG, Pfizer, Inc. Takeda Pharmaceutical Co., Ltd., AstraZeneca plc, Daiichi Sankyo Company, Sanofi S.A., and Novartis International AG.

Key Benefits for Stakeholders:

  • This report entails a detailed quantitative analysis along with the current global antihyperlipidemic drugs market trends from 2019 to 2026 to identify the prevailing opportunities along with the strategic assessment.
  • The antihyperlipidemic drugs market forecast is studied from 2019 to 2026. 
  • The market size and estimations are based on a comprehensive analysis of key developments in the industry. 
  • A qualitative analysis based on innovative products facilitates strategic business planning.
  • The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market

Key Market Segments:

By Drug Class

  • Statins
  • PCSK9 Inhibitors
  • Bile Acid Sequestrants
  • Cholesterol Absorption Inhibitors
  • Fibric Acid Derivatives
  • Combination
  • Symptoms Check

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany 
    • France 
    • UK 
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan 
    • China 
    • India 
    • Australia 
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil 
    • Saudi Arabia 
    • South Africa
    • Rest of LAMEA
 

CHAPTER 1: INTRODUCTION

1.1. Report description 
1.2. Key market segments

1.2.1. List of key players profiled in the report

1.3. Research methodology

1.3.1. Primary research
1.3.2. Secondary research
1.3.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. Key findings of the study
2.2. CXO perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Top player positioning

3.2.1. Top investment pockets

3.3. Key forces shaping antihyperlipidemic industry/market
3.4. Market dynamics

3.4.1. Drivers

3.4.1.1. Presence of guidelines recommending the use of statins
3.4.1.2. Surge in healthcare expenditure worldwide
3.4.1.3. Rise in prevalence of hyperlipidemia across  the globe

3.4.2. Restraint

3.4.2.1. Upcoming patent expirations of drugs

3.4.3. Opportunity

3.4.3.1. High growth potential in developing economies

3.4.4. Impact Analyses

CHAPTER 4: ANTIHYPERLIPIDEMIC DRUGS MARKET, BY DRUG CLASS

4.1. Overview

4.1.1. Market size and forecast

4.2. Statins

4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis by country

4.3. Bile Acid Sequestrants

4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis by country

4.4. Cholesterol Absorption Inhibitors

4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis by country

4.5. Fibric Acid Derivatives

4.5.1. Key market trends, growth factors, and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market analysis by country

4.6. PCSK9 Inhibitors

4.6.1. Key market trends, growth factors, and opportunities
4.6.2. Market size and forecast, by region
4.6.3. Market analysis by country

4.7. Combination

4.7.1. Key market trends, growth factors, and opportunities
4.7.2. Market size and forecast, by region
4.7.3. Market analysis by country

4.8. Others

4.8.1. Key market trends, growth factors, and opportunities
4.8.2. Market size and forecast, by region
4.8.3. Market analysis by country

CHAPTER 5: ANTIHYPERLIPIDEMIC DRUGS MARKET, BY REGION

5.1. Overview

5.1.1. Market size and forecast

5.2. North America

5.2.1. Key market trends and opportunities
5.2.2. Market analysis, by country

5.2.2.1. U.S.

5.2.2.1.1. U.S. market size and forecast, by drug class

5.2.2.2. Canada

5.2.2.2.1. Canada market size and forecast, by drug class

5.2.2.3. Mexico

5.2.2.3.1. Mexico market size and forecast, by drug class

5.2.3. North America market size and forecast, by drug class

5.3. Europe

5.3.1. Key market trends and opportunities
5.3.2. Market analysis, by country

5.3.2.1. Germany

5.3.2.1.1. Germany market size and forecast, by drug class

5.3.2.2. France

5.3.2.2.1. France market size and forecast, by drug class

5.3.2.3. UK

5.3.2.3.1. UK market size and forecast, by drug class

5.3.2.4. Italy

5.3.2.4.1. Italy market size and forecast, by drug class

5.3.2.5. Rest of Europe

5.3.2.5.1. Rest of Europe market size and forecast, by drug class

5.3.3. Europe market size and forecast, by drug class

5.4. Asia-Pacific

5.4.1. Key market trends and opportunities
5.4.2. Market analysis, by country

5.4.2.1. Japan

5.4.2.1.1. Japan market size and forecast, by drug class

5.4.2.2. China

5.4.2.2.1. China market size and forecast, by drug class

5.4.2.3. India

5.4.2.3.1. India market size and forecast, by drug class

5.4.2.4. Rest of Asia-Pacific

5.4.2.4.1. Rest of Asia-Pacific market size and forecast, by drug class

5.4.3. Asia-Pacific market size and forecast, by drug class

5.5. LAMEA

5.5.1. Key market trends and opportunities
5.5.2. Market analysis, by country

5.5.2.1. Brazil

5.5.2.1.1. Brazil market size and forecast, by drug class

5.5.2.2. South Africa

5.5.2.2.1. South Africa market size and forecast, by drug class

5.5.2.3. Saudi Arabia

5.5.2.3.1. Saudi Arabia market size and forecast, by drug class

5.5.2.4. Rest of LAMEA

5.5.2.4.1. Rest of LAMEA market size and forecast, by drug class

5.5.3. LAMEA market size and forecast, by drug class

CHAPTER 6: COMPANY PROFILES

6.1. ABBVIE INC.

6.1.1. Company overview
6.1.2. Company snapshot
6.1.3. Operating business segments
6.1.4. Product portfolio
6.1.5. Business performance

6.2. Amgen Inc.

6.2.1. Company overview
6.2.2. Company snapshot
6.2.3. Operating business segments
6.2.4. Product portfolio
6.2.5. Business performance
6.2.6. Key strategic moves and developments

6.3. AstraZeneca plc

6.3.1. Company overview
6.3.2. Company snapshot
6.3.3. Operating business segments
6.3.4. Product portfolio
6.3.5. Business performance

6.4. Bristol-Myers Squibb Company

6.4.1. Company overview
6.4.2. Company snapshot
6.4.3. Operating business segments
6.4.4. Product portfolio
6.4.5. Business performance

6.5. Daiichi Sankyo Company, Limited

6.5.1. Company overview
6.5.2. Operating business segments
6.5.3. Product portfolio
6.5.4. Business performance

6.6. Dr. Reddy’s Laboratories Ltd

6.6.1. Company overview
6.6.2. Company snapshot
6.6.3. Operating business segments
6.6.4. Product portfolio
6.6.5. Business performance

6.7. Merck & Co., Inc

6.7.1. Company overview
6.7.2. Company snapshot
6.7.3. Operating business segments
6.7.4. Product portfolio
6.7.5. Business performance

6.8. Mylan N.V

6.8.1. Company overview
6.8.2. Company snapshot
6.8.3. Operating business segments
6.8.4. Product portfolio
6.8.5. Business performance

6.9. Pfizer Inc.

6.9.1. Company overview
6.9.2. Company snapshot
6.9.3. Operating business segments
6.9.4. Product portfolio
6.9.5. Business performance

6.10. SANOFI S.A.

6.10.1. Company overview
6.10.2. Operating business segments
6.10.3. Product portfolio
6.10.4. Business performance
6.10.5. Key strategic moves and developments

LIST OF TABLES

TABLE 01. GLOBAL ANTIHYPERLIPIDEMIC DRUGS MARKET, BY DRUG CLASS, 2018-2026 ($MILLION )
TABLE 02. STATINS ANTIHYPERLIPIDEMIC DRUGS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 03. BILE ACID SEQUESTRANTS ANTIHYPERLIPIDEMIC DRUGS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 04. CHOLESTEROL ABSORPTION INHIBITORS ANTIHYPERLIPIDEMIC DRUGS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 05. FIBRIC ACID DERIVATIVES ANTIHYPERLIPIDEMIC DRUGS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 06. PCSK9 INHIBITORS ANTIHYPERLIPIDEMIC DRUGS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 07. COMBINATION ANTIHYPERLIPIDEMIC DRUGS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 08. OTHERS ANTIHYPERLIPIDEMIC DRUGS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 09. ANTIHYPERLIPIDEMIC DRUGS MARKET, BY REGION, 2018-2026 ($MILLION )
TABLE 10. NORTH AMERICA ANTIHYPERLIPIDEMIC DRUGS MARKET REVENUE, BY COUNTRY, 2019–2026 ($MILLION)
TABLE 11. U.S. ANTIHYPERLIPIDEMIC DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION)
TABLE 12. CANADA ANTIHYPERLIPIDEMIC DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION)
TABLE 13. MEXICO ANTIHYPERLIPIDEMIC DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION)
TABLE 14. NORTH AMERICA ANTIHYPERLIPIDEMIC DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026($MILLION)
TABLE 15. EUROPE ANTIHYPERLIPIDEMIC DRUGS MARKET REVENUE, BY COUNTRY, 2019–2026 ($MILLION)
TABLE 16. GERMANY ANTIHYPERLIPIDEMIC DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION)
TABLE 17. FRANCE ANTIHYPERLIPIDEMIC DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION)
TABLE 18. UK ANTIHYPERLIPIDEMIC DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION)
TABLE 19. ITALY ANTIHYPERLIPIDEMIC DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION)
TABLE 20. REST OF EUROPE ANTIHYPERLIPIDEMIC DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION)
TABLE 21. EUROPE ANTIHYPERLIPIDEMIC DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026($MILLION)
TABLE 22. ASIA-PACIFIC ANTIHYPERLIPIDEMIC DRUGS MARKET REVENUE, BY COUNTRY, 2019–2026 ($MILLION)
TABLE 23. JAPAN ANTIHYPERLIPIDEMIC DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION)
TABLE 24. CHINA ANTIHYPERLIPIDEMIC DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION)
TABLE 25. INDIA ANTIHYPERLIPIDEMIC DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION)
TABLE 26. REST OF ASIA-PACIFIC ANTIHYPERLIPIDEMIC DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION)
TABLE 27. ASIA-PACIFIC ANTIHYPERLIPIDEMIC DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026($MILLION)
TABLE 28. LAMEA ANTIHYPERLIPIDEMIC DRUGS MARKET REVENUE, BY COUNTRY, 2019–2026 ($MILLION)
TABLE 29. BRAZIL ANTIHYPERLIPIDEMIC DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION)
TABLE 30. SOUTH AFRICA ANTIHYPERLIPIDEMIC DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION)
TABLE 31. SAUDI ARABIA ANTIHYPERLIPIDEMIC DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION)
TABLE 32. REST OF LAMEA ANTIHYPERLIPIDEMIC DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION)
TABLE 33. LAMEA ANTIHYPERLIPIDEMIC DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026($MILLION)
TABLE 34. ABBVIE: COMPANY SNAPSHOT
TABLE 35. ABBVIE: OPERATING BUSINESS SEGMENTS
TABLE 36. ABBVIE: PRODUCT PORTFOLIO
TABLE 37. AMGEN: COMPANY SNAPSHOT
TABLE 38. AMGEN: PRODUCT BUSINESS SEGMENT
TABLE 39. AMGEN: PRODUCT PORTFOLIO
TABLE 40. ASTRAZENECA: COMPANY SNAPSHOT
TABLE 41. ASTRAZENECA: OPERATING BUSINESS SEGMENTS
TABLE 42. ASTRAZENECA: PRODUCT PORTFOLIO
TABLE 43. BMS: COMPANY SNAPSHOT
TABLE 44. BMS: OPERATING SEGMENTS
TABLE 45. BMS: PRODUCT PORTFOLIO
TABLE 46. DAIICHI-SANKYO.: COMPANY SNAPSHOT
TABLE 47. DAIICHI-SANKYO.: OPERATING BUSINESS SEGMENTS
TABLE 48. DAIICHI-SANKYO.: PRODUCT PORTFOLIO
TABLE 49. DR.REDDY'S: COMPANY SNAPSHOT
TABLE 50. DR. REDDY’S: OPERATING BUSINESS SEGMENTS
TABLE 51. DR. REDDY’S: PRODUCT PORTFOLIO
TABLE 52. MERCK: COMPANY SNAPSHOT
TABLE 53. MERCK: OPERATING SEGMENTS
TABLE 54. MERCK: PRODUCT PORTFOLIO
TABLE 55. MYLAN: COMPANY SNAPSHOT
TABLE 56. MYLAN: OPERATING SEGMENTS
TABLE 57. MYLAN: PRODUCT PORTFOLIO
TABLE 58. PFIZER: COMPANY SNAPSHOT
TABLE 59. PFIZER: OPERATING SEGMENTS
TABLE 60. PFIZER: PRODUCT PORTFOLIO
TABLE 61. SANOFI: COMPANY SNAPSHOT
TABLE 62. SANOFI: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01. GLOBAL ANTIHYPERLIPIDEMIC DRUGS MARKET SEGMENTATION
FIGURE 02. TOP PLAYER POSITIONING, 2018
FIGURE 03. TOP INVESTMENT POCKETS
FIGURE 04. MODERATE BARGAINING POWER OF SUPPLIER
FIGURE 05. LOW BARGAINING POWER OF BUYERS
FIGURE 06. LOW THREAT OF SUBSTITUTES
FIGURE 07. HIGH INTENSITY OF RIVALRY
FIGURE 08. LOW THREAT OF NEW ENTRANT
FIGURE 09. IMPACT ANALYSES, ANTIHYPERLIPIDEMIC DRUGS MARKET
FIGURE 10. COMPARATIVE SHARE ANALYSIS OF STATINS ANTIHYPERLIPIDEMIC DRUGS MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 11. COMPARATIVE SHARE ANALYSIS OF BILE ACID SEQUESTRANTS ANTIHYPERLIPIDEMIC DRUGS MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF CHOLESTEROL ABSORPTION INHIBITORS ANTIHYPERLIPIDEMIC DRUGS MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF FIBRIC ACID DERIVATIVES ANTIHYPERLIPIDEMIC DRUGS MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF PCSK9 INHIBITORS ANTIHYPERLIPIDEMIC DRUGS MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 15. COMPARATIVE SHARE ANALYSIS OF COMBINATION ANTIHYPERLIPIDEMIC DRUGS MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF OTHERS ANTIHYPERLIPIDEMIC DRUGS MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 17. U.S. ANTIHYPERLIPIDEMIC DRUGS MARKET, 2018-2026 ($MILLION)
FIGURE 18. CANADA ANTIHYPERLIPIDEMIC DRUGS MARKET, 2018-2026 ($MILLION)
FIGURE 19. MEXICO ANTIHYPERLIPIDEMIC DRUGS MARKET, 2018-2026 ($MILLION)
FIGURE 20. GERMANY ANTIHYPERLIPIDEMIC DRUGS MARKET, 2018-2026 ($MILLION)
FIGURE 21. FRANCE ANTIHYPERLIPIDEMIC DRUGS MARKET, 2018-2026 ($MILLION)
FIGURE 22. UK ANTIHYPERLIPIDEMIC DRUGS MARKET, 2018-2026 ($MILLION)
FIGURE 23. ITALY ANTIHYPERLIPIDEMIC DRUGS MARKET, 2018-2026 ($MILLION)
FIGURE 24. REST OF EUROPE ANTIHYPERLIPIDEMIC DRUGS MARKET, 2018-2026 ($MILLION)
FIGURE 25. JAPAN ANTIHYPERLIPIDEMIC DRUGS MARKET, 2018-2026 ($MILLION)
FIGURE 26. CHINA ANTIHYPERLIPIDEMIC DRUGS MARKET, 2018-2026 ($MILLION)
FIGURE 27. INDIA ANTIHYPERLIPIDEMIC DRUGS MARKET, 2018-2026 ($MILLION)
FIGURE 28. REST OF ASIA-PACIFIC ANTIHYPERLIPIDEMIC DRUGS MARKET, 2018-2026 ($MILLION)
FIGURE 29. BRAZIL ANTIHYPERLIPIDEMIC DRUGS MARKET, 2018-2026 ($MILLION)
FIGURE 30. SOUTH AFRICA ANTIHYPERLIPIDEMIC DRUGS MARKET, 2018-2026 ($MILLION)
FIGURE 31. SAUDI ARABIA ANTIHYPERLIPIDEMIC DRUGS MARKET, 2018-2026 ($MILLION)
FIGURE 32. REST OF LAMEA ANTIHYPERLIPIDEMIC DRUGS MARKET, 2018-2026 ($MILLION)
FIGURE 33. ABBVIE: NET SALES, 2016–2018 ($MILLION)
FIGURE 34. ABBVIE: REVENUE SHARE BY REGION, 2018(%)
FIGURE 35. AMGEN: NET SALES, 2016–2018 ($MILLION)
FIGURE 36. AMGEN: REVENUE SHARE BY REGION, 2018(%)
FIGURE 37. ASTRAZENECA: NET SALES, 2016–2018 ($MILLION)
FIGURE 38. ASTRAZENECA: REVENUE SHARE BY REGION, 2018(%)
FIGURE 39. BMS: NET SALES, 2016–2018 ($MILLION)
FIGURE 40. BMS: REVENUE SHARE BY REGION, 2018(%)
FIGURE 41. DAIICHI-SANKYO: NET SALES, 2016–2018 ($MILLION)
FIGURE 42. DAIICHI-SANKYO: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 43. DAIICHI-SANKYO: REVENUE SHARE BY REGION, 2018(%)
FIGURE 44. DR. REDDY’S: NET SALES, 2016–2018 ($MILLION)
FIGURE 45. DR. REDDY’S: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 46. DR. REDDY’S: REVENUE SHARE BY REGION, 2018(%)
FIGURE 47. MERCK: NET SALES, 2016–2018 ($MILLION)
FIGURE 48. MERCK: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 49. MERCK: REVENUE SHARE BY REGION, 2018(%)
FIGURE 50. MYLAN: NET SALES, 2016–2018 ($MILLION)
FIGURE 51. MYLAN: REVENUE SHARE BY GEOGRAPHY, 2018 (%)
FIGURE 52. PFIZER: NET SALES, 2016–2018 ($MILLION)
FIGURE 53. PFIZER: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 54. PFIZER: REVENUE SHARE BY REGION, 2018(%)
FIGURE 55. SANOFI: NET SALES, 2016–2018 ($MILLION)
FIGURE 56. SANOFI: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 57. SANOFI: REVENUE SHARE BY REGION, 2018(%)

 
 

Hyperlipidemia is a medical condition, which occur due to rise in level of lipids in the blood. This leads to deposition of plaque in the arteries; thereby, narrowing them. This can also lead to blockage, which increases the risk of heath attack. The treatment of this condition involves utilization of anti-hyperlipidemic drugs. These drugs are used to control the level of lipids in the blood.

The utilization of anti-hyperlipidemic has witnessed a significant growth, owing to surge in sedentary lifestyle. Moreover, rise in incidence of disorders related to distributed cholesterol levels in the blood also contributes to the growth of the anti-hyperlipidemics market. Moreover, surge in awareness regarding complications related with hyperlipidemia is another major factor that fuels the growth of the market. However, factors such as high cost of the treatment hinders the growth of the market. Conversely, growth opportunities exhibited by emerging economies is expected to offer lucrative opportunities during the forecast period

 

PURCHASE OPTIONS

Start reading instantly ,This title and over 12000 thousand more,available with Avenue Library,  T&C*

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,   
Int'l : +1-503-894-6022
( Europe )
+ 44-845-528-1300
Drop us an email at
help@alliedmarketresearch.com

FREQUENTLY ASKED QUESTIONS?
 

A. The total market value of antihyperlipidemic drugs market is $9456.00 million in 2018.

A. The forcast period for antihyperlipidemic drugs market is 2019 to 2026

A. The market value of antihyperlipidemic drugs market in 2019 is $10165.2 million

A. The base year is 2018 in antihyperlipidemic drugs market

A. Top companies such as, AstraZeneca plc, Pfizer Inc., Abbvie Inc., Amgen Inc., and Daiichi Sankyo Company, Limited held a high market position in 2018. These key players held a high market postion owing to the strong geographical foothold in different regions.

A. Statins segment is the most influencing segment growing in the antihyperlipidemic drugs market owing to the additional benefits offered by the statins such as improved endothelial function, enhance the stability of atherosclerotic plaques, and reduce the amount of inflammation & damage done to cells due to oxidative stress

A. The key trend in the antihyperlipidemic drugs market is the rise in prevalence of hyperlipidemia across the globe which drives the growth of the market. This leads to surge in the demand for antihyperlipidemic drugs which boots the growth of the market.

A. Asia-Pacific has the highest growth rate in the market which is growing due to the contribution of the following emerging countries such as India with a CAGR of 10.5%. This is due to surge in the awaresness related to early diagnosis and treatment of hyperlipidemia.

A. Antihyperlipidemic drugs are agents that promote reduction of lipid levels in the blood. Furthermore, antihyperlipidemic agents aim to lower the levels of low-density lipoprotein in the body to treat the condition called as hyperlipidemia

A. Antihyperlipidemic drugs are used to lower the level of bad cholestrol in the body which has the tendency to block the arteries causing variuos medical conditions such as Atherosclerosis.

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 

Download Sample

OR

Purchase Full Report of
Antihyperlipidemic Drugs Market

  • Online Only
  • $3,456
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Single User
  • $5,769
  • Restricted to one authorized user
  • One print only
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Five Users
  • $6,450
  • Limited to five authorized users
  • Print upto five copies
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Enterprise
    License/PDF

  • $8,995
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Library Membership
  • $ 699/mo
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Start reading instantly.
    This title and over 12,000+ are available on the Avenue Library.  T&C*.

    Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 

Featured Readings

 

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts